T. Rowe Price Associates
TMCI icon

T. Rowe Price Associates’s Treace Medical Concepts TMCI Stock Holding History

T. Rowe Price Associates’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,627
Closed -$35K – 3334
2026
Q1 		$35K Hold
25,627
– – ﹤0.01% 3090
2025
Q4 		$63K Hold
25,627
– – ﹤0.01% 3012
2025
Q3 		$172K Buy
25,627
+3,510
+16% +$22.9K ﹤0.01% 2825
2025
Q2 		$131K Buy
22,117
+1,118
+5% +$7.28K ﹤0.01% 2838
2025
Q1 		$177K Buy
20,999
+1,943
+10% +$17.5K ﹤0.01% 2691
2024
Q4 		$142K Buy
19,056
+3,452
+22% +$23.1K ﹤0.01% 2779
2024
Q3 		$91K Hold
15,604
– – ﹤0.01% 2838
2024
Q2 		$104K Buy
15,604
+2,632
+20% +$21.3K ﹤0.01% 2755
2024
Q1 		$170K Buy
12,972
+1,385
+12% +$18.5K ﹤0.01% 2667
2023
Q4 		$148K Buy
11,587
+1,107
+11% +$11.2K ﹤0.01% 2634
2023
Q3 		$138K Buy
10,480
+1,323
+14% +$24.2K ﹤0.01% 2596
2023
Q2 		$235K Buy
+9,157
New +$236K ﹤0.01% 2469

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

T. Rowe Price Associates's TMCI Position: Q2 2026 in Review

T. Rowe Price Associates sold out of Treace Medical Concepts (TMCI) in Q2 2026, closing a stake of 25,627 shares — an estimated $35K sold.

T. Rowe Price Associates first reported a position in TMCI in Q2 2023 and held it in 12 quarters. The position peaked at $235K in Q2 2023. 116 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • T. Rowe Price Associates reported no remaining Treace Medical Concepts position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 25,627 Treace Medical Concepts shares in Q2 2026, an estimated $35K.
  • T. Rowe Price Associates first reported a position in Treace Medical Concepts in Q2 2023 and held it in 12 quarters.
  • T. Rowe Price Associates's Treace Medical Concepts position peaked at $235K in Q2 2023.
  • 116 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.